Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals

Set Alert for Deals

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

StartUps and SMEs Deals

Iovance TIL Appeal Seen Luring Potential Buyers

Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.

Companies ImmunoOncology

Deal Watch: Genentech Sees Bicycle As Route To Novel Targeted Cancer Immunotherapies

Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.

Deals Business Strategies

RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.

Deals Gastrointestinal

GSK Partnership With Immatics Seeks TCR Therapeutics For Solid Tumors

Deal Snapshot: GSK obtains rights to two of Immatics’ TCR targets, following on the German firm’s similar deals in recent years with Celgene, Genmab and Amgen.

Deals Business Strategies

Reverse Merger With Tocagen Takes Forte’s Dermatology Ambitions Public

Deal Snapshot: Forte finds a route to the public markets to support moving its atopic dermatitis drug into Phase II; most of Tocagen’s assets will be sold off.

Deals M & A

Tech Transfer Roundup: Be Cool Therapeutics Sees Potential In Mimicking Hibernation

Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.

Deals Business Strategies

Sobi Reaps Benefits From Acquisitions, Commercial Focus

Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.

Sales & Earnings Deals

Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics

Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…

Deals Business Strategies
See All
UsernamePublicRestriction

Register